ALMS announces topline results from Envudeucitinib Phase 2b in SLE
Alumis said it has topline initial high-level results from its Envudeucitinib Phase 2b trial in systemic lupus erythematosus (SLE).
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Alumis said it has topline initial high-level results from its Envudeucitinib Phase 2b trial in systemic lupus erythematosus (SLE).